Features include Headlines, Commentaries, Conference Coverage and Videos.
Browsing: Features
Patients now living a median 6.8 years after stage IV ALK positive lung cancer diagnosis
According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between…
‘Christmas berry’ plant compound could fight Uveal melanoma
Doctors diagnose about 2000 adults with uveal melanoma, a cancer of the eye, every year.…
An errant editing enzyme promotes tumour suppressor loss and leukaemia propagation
Writing in the journal Cancer Cell, researchers at University of California San Diego School of Medicine…
Study reveals how solid stress from brain tumours causes neuronal loss, neurologic dysfunction
A Massachusetts General Hospital (MGH)-led research team has demonstrated, for the first time, how solid…
New reference values for cancer patients’ quality of life
Researchers and practitioners across the globe frequently use the ‘EORTC’ questionnaire to measure self-reported quality…
AYA World Cancer Congress Review by Ian Olver
Report on 3rd Annual Global Adolescent and Young Adult Cancer Congress, December 4-6th Sydney, Australia…
Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk…
Researchers develop personalised medicine tool for inherited colorectal cancer syndrome
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of…
SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer
Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they…
SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemotherapy
Pathological complete response (pCR) after neoadjuvant (presurgery) chemotherapy was associated with significantly lower recurrence risk…